首页 > 最新文献

Vacunas (English Edition)最新文献

英文 中文
Whooping cough outbreaks in 2024. Can immunisation strategies be improved? 2024 年百日咳爆发。能否改进免疫战略?
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.015
Fernando Moraga-Llop
{"title":"Whooping cough outbreaks in 2024. Can immunisation strategies be improved?","authors":"Fernando Moraga-Llop","doi":"10.1016/j.vacune.2024.05.015","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.015","url":null,"abstract":"","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 149-151"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141322445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 vaccination and web search on mental health: A worldwide infodemiological study COVID-19 疫苗接种和有关心理健康的网络搜索:一项全球信息神经病学研究
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.04.002
Juan Antonio Becerra-García , Sara Barbeito , Teresa Sánchez-Gutiérrez

Background

The association between worldwide COVID-19 vaccination and mental health has been largely unexplored by means of infodemiological studies.

Objective

To explore how global public interest in different mental health topics changed between the pre-vaccination pandemic stage and the different periods of the COVID-19 vaccination campaign.

Methods

In this study were examined the relative search volume (RSV) in Google Trends for ‘anxiety’, ‘depression’, ‘stress’, and ‘suicide’ between 1 March 2020 and 1 January 2023. The RSV for each term was compared with respect to 4 periods: the pre-vaccination pandemic stage; the period from initiation of vaccination until 50% of the population was fully vaccinated (FV); the period from 50% FV to 60% FV; and the period after 60% FV.

Results

A significant lower mean RSV on anxiety, depression, and suicide was found once 60% of the world population had been FV compared to different previous vaccination periods and with the pre-vaccination pandemic stage.

Conclusions

There seems to be less need for information worldwide on anxiety, depression, and suicide topics once 60% of the population is FV against COVID-19. Overcoming this vaccination milestone may have had a positive impact on public interest in specific mental health issues.

背景全球范围内的 COVID-19 疫苗接种与心理健康之间的关系在很大程度上尚未通过信息神经学研究得到探讨。每个词的 RSV 都与 4 个时期进行了比较:疫苗接种前的大流行阶段;从开始接种疫苗到 50%的人完全接种疫苗(FV)的时期;从 50% FV 到 60% FV 的时期;以及 60% FV 之后的时期。结论一旦 60% 的人口接种了 COVID-19 疫苗,全球范围内对焦虑、抑郁和自杀主题信息的需求似乎就会减少。跨越这一疫苗接种里程碑可能会对公众对特定心理健康问题的兴趣产生积极影响。
{"title":"COVID-19 vaccination and web search on mental health: A worldwide infodemiological study","authors":"Juan Antonio Becerra-García ,&nbsp;Sara Barbeito ,&nbsp;Teresa Sánchez-Gutiérrez","doi":"10.1016/j.vacune.2024.04.002","DOIUrl":"10.1016/j.vacune.2024.04.002","url":null,"abstract":"<div><h3>Background</h3><p>The association between worldwide COVID-19 vaccination and mental health has been largely unexplored by means of infodemiological studies.</p></div><div><h3>Objective</h3><p>To explore how global public interest in different mental health topics changed between the pre-vaccination pandemic stage and the different periods of the COVID-19 vaccination campaign.</p></div><div><h3>Methods</h3><p>In this study were examined the relative search volume (RSV) in Google Trends for ‘anxiety’, ‘depression’, ‘stress’, and ‘suicide’ between 1 March 2020 and 1 January 2023. The RSV for each term was compared with respect to 4 periods: the pre-vaccination pandemic stage; the period from initiation of vaccination until 50% of the population was fully vaccinated (FV); the period from 50% FV to 60% FV; and the period after 60% FV.</p></div><div><h3>Results</h3><p>A significant lower mean RSV on anxiety, depression, and suicide was found once 60% of the world population had been FV compared to different previous vaccination periods and with the pre-vaccination pandemic stage.</p></div><div><h3>Conclusions</h3><p>There seems to be less need for information worldwide on anxiety, depression, and suicide topics once 60% of the population is FV against COVID-19. Overcoming this vaccination milestone may have had a positive impact on public interest in specific mental health issues.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 224-227"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141057703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review on non-small cell lung cancer 非小细胞肺癌综述
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.013
Sunil Kumar Verma , Minakshi Pandey , Renu Khare , Devendra Singh

Lung cancer is among the leading causes of death related to cancer globally, with NSCLC (non-small cell lung cancer) accounting for about 85% of all cases. NSCLC is characterized by a complex genetic landscape, with multiple driver mutations and epigenetic alterations that promote tumor progression and resistance to therapy. NSCLC is treated with immunotherapy, chemotherapy, radiation, surgery, or molecularly targeted therapy. However, a significant number of patients who had surgery are likely to experience local recurrence or distant metastases. Immunotherapy and targeted therapies have advanced rapidly in the last few years. Here, in this review, details related to NSCLC, its types, preventive measures, and risk factors, their symptoms, method of screening, diagnosis, and related treatment, and the latest updates related to NSCLC are discussed.

肺癌是全球癌症死亡的主要原因之一,NSCLC(非小细胞肺癌)约占所有病例的 85%。NSCLC 具有复杂的遗传特征,多种驱动基因突变和表观遗传学改变会促进肿瘤进展和耐药性。NSCLC 可通过免疫疗法、化疗、放疗、手术或分子靶向疗法进行治疗。然而,大量接受过手术的患者很可能会出现局部复发或远处转移。最近几年,免疫疗法和靶向疗法发展迅速。在这篇综述中,我们将讨论非小细胞肺癌的相关细节、类型、预防措施和风险因素、症状、筛查方法、诊断和相关治疗,以及非小细胞肺癌的最新进展。
{"title":"A review on non-small cell lung cancer","authors":"Sunil Kumar Verma ,&nbsp;Minakshi Pandey ,&nbsp;Renu Khare ,&nbsp;Devendra Singh","doi":"10.1016/j.vacune.2024.05.013","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.013","url":null,"abstract":"<div><p>Lung cancer is among the leading causes of death related to cancer globally, with NSCLC (non-small cell lung cancer) accounting for about 85% of all cases. NSCLC is characterized by a complex genetic landscape, with multiple driver mutations and epigenetic alterations that promote tumor progression and resistance to therapy. NSCLC is treated with immunotherapy, chemotherapy, radiation, surgery, or molecularly targeted therapy. However, a significant number of patients who had surgery are likely to experience local recurrence or distant metastases. Immunotherapy and targeted therapies have advanced rapidly in the last few years. Here, in this review, details related to NSCLC, its types, preventive measures, and risk factors, their symptoms, method of screening, diagnosis, and related treatment, and the latest updates related to NSCLC are discussed.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 239-253"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One Health approach to Nipah virus prevention 预防尼帕病毒的 "一种健康 "方法
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.014
Muhammad Safdar , Shafeeq ur Rehman , Muhammad Younus , Muhammad Arif Rizwan , Muhammad Kaleem , Mehmet Ozaslan

The Nipah virus (NiV) is a highly lethal disease, resulting in a mortality rate of 75%. Outbreaks have been observed in southeast Asian countries, including Singapore, Malaysia, Bangladesh, and India. As of September 24, 2023, 6 confirmed cases of the NiV had been reported, including 2 fatalities in the Kozhikode District in Northern Kerala, India. In January and February of 2023, this virus sparked an epidemic in Bangladesh. Bats are important hosts for zoonotic viruses such as the NiV, SARS-CoV-2, Ebola virus, and others; nevertheless, relatively little is known about the ecological determinants and dynamics of these viruses' propagation in their reservoir hosts. Therefore, this review assessed early detection, data integration, community awareness, and resource limitations. Moreover, it gives specific future directions, emphasizing the urgency of vaccine and antiviral development, genomic surveillance advancements, case studies, healthcare system reinforcement, and intensified global collaboration. By addressing these issues, the One Health approach emerges as a vital and proactive strategy for NiV prevention, ensuring comprehensive preparedness and response mechanisms against future outbreaks.

尼帕病毒(NiV)是一种高度致命的疾病,死亡率高达 75%。新加坡、马来西亚、孟加拉国和印度等东南亚国家都爆发过疫情。截至 2023 年 9 月 24 日,印度喀拉拉邦北部的科济科德地区共报告了 6 例 NiV 确诊病例,其中 2 例死亡。2023 年 1 月和 2 月,这种病毒在孟加拉国引发了一场流行病。蝙蝠是NiV、SARS-CoV-2、埃博拉病毒等人畜共患病毒的重要宿主;然而,人们对这些病毒在宿主体内传播的生态决定因素和动态却知之甚少。因此,本综述对早期检测、数据整合、社区意识和资源限制进行了评估。此外,它还给出了未来的具体方向,强调了疫苗和抗病毒开发、基因组监测进展、案例研究、医疗保健系统强化和加强全球合作的紧迫性。通过解决这些问题,"一体健康 "方法将成为预防尼罗河病毒的一项重要而积极的战略,确保针对未来疫情爆发的全面准备和响应机制。
{"title":"One Health approach to Nipah virus prevention","authors":"Muhammad Safdar ,&nbsp;Shafeeq ur Rehman ,&nbsp;Muhammad Younus ,&nbsp;Muhammad Arif Rizwan ,&nbsp;Muhammad Kaleem ,&nbsp;Mehmet Ozaslan","doi":"10.1016/j.vacune.2024.05.014","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.014","url":null,"abstract":"<div><p>The Nipah virus (NiV) is a highly lethal disease, resulting in a mortality rate of 75%. Outbreaks have been observed in southeast Asian countries, including Singapore, Malaysia, Bangladesh, and India. As of September 24, 2023, 6 confirmed cases of the NiV had been reported, including 2 fatalities in the Kozhikode District in Northern Kerala, India. In January and February of 2023, this virus sparked an epidemic in Bangladesh. Bats are important hosts for zoonotic viruses such as the NiV, SARS-CoV-2, Ebola virus, and others; nevertheless, relatively little is known about the ecological determinants and dynamics of these viruses' propagation in their reservoir hosts. Therefore, this review assessed early detection, data integration, community awareness, and resource limitations. Moreover, it gives specific future directions, emphasizing the urgency of vaccine and antiviral development, genomic surveillance advancements, case studies, healthcare system reinforcement, and intensified global collaboration. By addressing these issues, the One Health approach emerges as a vital and proactive strategy for NiV prevention, ensuring comprehensive preparedness and response mechanisms against future outbreaks.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 264-273"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of lymphocytosis among pertussis patients in Northwest Ethiopia 评估埃塞俄比亚西北部百日咳患者的淋巴细胞增多症
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.007
Solomon Taye Sima , Debasu Damtie , Belay Tessema , Baye Gelaw , Feleke Moges

Background

Pertussis is a severe and prolonged coughing disease caused by Bordetella pertussis. In 2014, 24.1 million pertussis cases and 160 700 deaths were estimated worldwide in children less than 5 years old. Infection with B. pertussis is frequently characterized by a significant rise in the number of circulating lymphocytes. Thus, the objective of this study was to assess lymphocytosis among pertussis patients in Northwest Ethiopia.

Methods

An institution-based cross-sectional study was conducted among pertussis patients who met the clinical case definition for pertussis. The study was conducted from July 2018 through February 2019 and nasopharyngeal swabs were collected from 321 participants, and samples were analyzed using real-time PCR (RT-PCR). Blood specimens were collected from 321 study participants and total lymphocyte count was conducted using hematology analyzer.

Results

A total of 109 participants were positive for Bordetella species. Lymphocytosis was found in 15/109 (13.8%) of the PCR confirmed pertussis patients. Of those 15 PCR confirmed participants with lymphocytosis, 8/15 (53.3%) had lymphocytosis grading ‘high’ (≥ 2.81/μL) followed by 3/15 (20.0%) ‘moderately high’ (≥ 4.0/μL), and 4/15 (26.7%) had ‘very high’ (≥ 6.0/μL). Among PCR confirmed pertussis participants with lymphocytosis, 11/15 (73.3%) were less than 1 year old.

Conclusions

Despite other co-infections can cause lymphocytosis, this study showed that lymphocyte count could be used to rule out pertussis. Thus, in combination with other specific laboratory tests, lymphocyte count in pertussis suspected patients is recommended.

背景百日咳是由百日咳杆菌引起的一种严重而持久的咳嗽疾病。据估计,2014 年全球有 2410 万例百日咳病例和 160 700 例死亡病例发生在 5 岁以下儿童身上。感染百日咳杆菌后,循环淋巴细胞数量通常会显著增加。因此,本研究旨在评估埃塞俄比亚西北部百日咳患者的淋巴细胞增多情况。方法对符合百日咳临床病例定义的百日咳患者进行了一项基于机构的横断面研究。研究于2018年7月至2019年2月进行,收集了321名参与者的鼻咽拭子,并使用实时PCR(RT-PCR)对样本进行分析。从 321 名研究参与者中采集了血液标本,并使用血液分析仪进行了总淋巴细胞计数。在 PCR 确诊的百日咳患者中,有 15/109 人(13.8%)出现淋巴细胞增多。在这15名经PCR确诊的淋巴细胞增多患者中,8/15(53.3%)的淋巴细胞增多分级为 "高"(≥ 2.81/μL),3/15(20.0%)为 "中高"(≥ 4.0/μL),4/15(26.7%)为 "极高"(≥ 6.0/μL)。结论尽管其他合并感染可导致淋巴细胞增多,但本研究表明淋巴细胞计数可用于排除百日咳。因此,建议对百日咳疑似患者进行淋巴细胞计数,并结合其他特异性实验室检查。
{"title":"Assessment of lymphocytosis among pertussis patients in Northwest Ethiopia","authors":"Solomon Taye Sima ,&nbsp;Debasu Damtie ,&nbsp;Belay Tessema ,&nbsp;Baye Gelaw ,&nbsp;Feleke Moges","doi":"10.1016/j.vacune.2024.05.007","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.007","url":null,"abstract":"<div><h3>Background</h3><p>Pertussis is a severe and prolonged coughing disease caused by <em>Bordetella pertussis</em>. In 2014, 24.1 million pertussis cases and 160 700 deaths were estimated worldwide in children less than 5 years old. Infection with <em>B. pertussis</em> is frequently characterized by a significant rise in the number of circulating lymphocytes. Thus, the objective of this study was to assess lymphocytosis among pertussis patients in Northwest Ethiopia.</p></div><div><h3>Methods</h3><p>An institution-based cross-sectional study was conducted among pertussis patients who met the clinical case definition for pertussis. The study was conducted from July 2018 through February 2019 and nasopharyngeal swabs were collected from 321 participants, and samples were analyzed using real-time PCR (RT-PCR). Blood specimens were collected from 321 study participants and total lymphocyte count was conducted using hematology analyzer.</p></div><div><h3>Results</h3><p>A total of 109 participants were positive for <em>Bordetella</em> species. Lymphocytosis was found in 15/109 (13.8%) of the PCR confirmed pertussis patients. Of those 15 PCR confirmed participants with lymphocytosis, 8/15 (53.3%) had lymphocytosis grading ‘high’ (≥<!--> <!-->2.81/μL) followed by 3/15 (20.0%) ‘moderately high’ (≥<!--> <!-->4.0/μL), and 4/15 (26.7%) had ‘very high’ (≥<!--> <!-->6.0/μL). Among PCR confirmed pertussis participants with lymphocytosis, 11/15 (73.3%) were less than 1 year old.</p></div><div><h3>Conclusions</h3><p>Despite other co-infections can cause lymphocytosis, this study showed that lymphocyte count could be used to rule out pertussis. Thus, in combination with other specific laboratory tests, lymphocyte count in pertussis suspected patients is recommended.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 174-180"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141324350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of the vaccine (Covaxin®) on different age groups of people: A pilot study 疫苗 (Covaxin®) 对不同年龄段人群的有效性:试点研究
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.005
Vivek Chauhan , Adrija Rakshit , Vivek Kumar Dhiman , Gaytri Mahajan , Akash Pnadey , Shamsher Singh Kanwar , Devendra Singh

Background

Covaxin® is a COVID-19 vaccine created and produced by Bharat Biotech in India. The vaccine is based on the strain of SARS-CoV-2 that was first identified in India and has undergone Phase III clinical trials. Covaxin® has been authorized for emergency use in India and has been distributed as part of India's vaccination campaign. The vaccine has been shown to be effective in preventing COVID-19 infection and hospitalization, but additional studies are needed to determine its efficacy as well as safety in the long term.

Methods

The antibody titer against Covaxin® was detected through indirect ELISA immunoassay. Optimization was performed on 500 samples to get an idea and work further on a larger number of samples.

Results

The vaccine had the best immune response in individuals between the ages of 21 and 30 and the least response in those between 61 and 70. This was attributed to the phenomenon of immunosenescence, which explains the weakening of the immune system with age. Additionally, the study found that the equine anti-CoV-19 serum had a higher binding affinity with Covaxin®, highlighting the effectiveness of horse Ig against COVID-19 antigens.

Conclusions

The study concluded that Covaxin® was effective in generating an immune response in individuals after 2 doses of vaccination; however, the generated immune response decreased with the time of vaccine administration and the age of the vaccinated. The study also showed that the ELISA technique used in this research is an efficient and sensitive method to evaluate vaccine efficiency and can be applied to a larger number of samples for further comparative analysis.

背景Covaxin®是印度Bharat生物技术公司创造和生产的COVID-19疫苗。该疫苗基于在印度首次发现的 SARS-CoV-2 株系,并已进行了 III 期临床试验。Covaxin® 已获准在印度紧急使用,并已作为印度疫苗接种活动的一部分分发。该疫苗已被证明可有效预防 COVID-19 感染和住院治疗,但仍需进行更多研究以确定其长期疗效和安全性。方法通过间接 ELISA 免疫测定法检测 Covaxin® 的抗体滴度。结果疫苗对 21-30 岁人群的免疫反应最好,而对 61-70 岁人群的反应最小。这归因于免疫衰老现象,即免疫系统随着年龄的增长而减弱。此外,研究还发现马的抗 COV-19 血清与 Covaxin® 的结合亲和力更高,这突出表明了马 Ig 对 COVID-19 抗原的有效性。结论该研究得出结论,Covaxin® 能有效地使接种 2 剂疫苗后的个体产生免疫反应;但是,产生的免疫反应会随着接种疫苗的时间和接种者的年龄而降低。研究还表明,本研究中使用的 ELISA 技术是一种高效、灵敏的疫苗效率评估方法,可应用于更多样本的进一步比较分析。
{"title":"Effectiveness of the vaccine (Covaxin®) on different age groups of people: A pilot study","authors":"Vivek Chauhan ,&nbsp;Adrija Rakshit ,&nbsp;Vivek Kumar Dhiman ,&nbsp;Gaytri Mahajan ,&nbsp;Akash Pnadey ,&nbsp;Shamsher Singh Kanwar ,&nbsp;Devendra Singh","doi":"10.1016/j.vacune.2024.05.005","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.005","url":null,"abstract":"<div><h3>Background</h3><p>Covaxin® is a COVID-19 vaccine created and produced by Bharat Biotech in India. The vaccine is based on the strain of SARS-CoV-2 that was first identified in India and has undergone Phase III clinical trials. Covaxin® has been authorized for emergency use in India and has been distributed as part of India's vaccination campaign. The vaccine has been shown to be effective in preventing COVID-19 infection and hospitalization, but additional studies are needed to determine its efficacy as well as safety in the long term.</p></div><div><h3>Methods</h3><p>The antibody titer against Covaxin® was detected through indirect ELISA immunoassay. Optimization was performed on 500 samples to get an idea and work further on a larger number of samples.</p></div><div><h3>Results</h3><p>The vaccine had the best immune response in individuals between the ages of 21 and 30 and the least response in those between 61 and 70. This was attributed to the phenomenon of immunosenescence, which explains the weakening of the immune system with age. Additionally, the study found that the equine anti-CoV-19 serum had a higher binding affinity with Covaxin®, highlighting the effectiveness of horse Ig against COVID-19 antigens.</p></div><div><h3>Conclusions</h3><p>The study concluded that Covaxin® was effective in generating an immune response in individuals after 2 doses of vaccination; however, the generated immune response decreased with the time of vaccine administration and the age of the vaccinated. The study also showed that the ELISA technique used in this research is an efficient and sensitive method to evaluate vaccine efficiency and can be applied to a larger number of samples for further comparative analysis.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 152-160"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141324370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of Omicron on the COVID-19 vaccines: A review Omicron 对 COVID-19 疫苗的影响:综述
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.004
Pragya D. Yadav , Deepak Y. Patil , Rima R. Sahay , Anita M. Shete , Sreelekshmy Mohandas , Velu Nair

The moment SARS-CoV-2 seemed to be receding; there was an uncertain emergence of Omicron variant which rapidly spread to all the 6 continents of the globe. The large number of genomic mutations has helped Omicron to evolve and become highly transmissible and escape the natural or vaccine-induced immune response. Until now, the Omicron has evolved into 5 unique lineages namely BA.1, BA.2, BA.3, BA.4, BA.5, and over 1000 sub-lineages. Despite vigorous COVID-19 immunisation programmes, India has been constantly being affected with emergence of new Omicron variants. In contrast to recovered patients following vaccination and breakthrough cases following a second dose against the Omicron variety, our recent research of naive Covishield vaccines showed declining immune response. The finding of this study and other studies with Covaxin depicted less immune response against Omicron post second dose of vaccination. This necessitates the administration of a preventive dose to improve immunity. There was surge in the COVID-19 cases with BA.5, BA.4, BF.7, BQ.1, XBB, and JN.1 infection which has greater transmissibility and vaccine efficacy remarkably dropped. Hence along with administration of booster dose, there is need to tweak the currently available vaccines with these SARS-CoV-2 variants. These types of modified boosters could provide enhances protection against SARS-CoV-2 infection.

就在 SARS-CoV-2 似乎正在消退的时候,不确定的 Omicron 变种出现了,并迅速蔓延到全球六大洲。大量的基因组突变帮助奥米克龙不断进化,变得极易传播,并能逃避自然或疫苗诱导的免疫反应。迄今为止,奥米克龙已进化为 5 个独特的品系,即 BA.1、BA.2、BA.3、BA.4 和 BA.5,以及 1000 多个亚品系。尽管印度大力开展了 COVID-19 免疫接种计划,但仍不断出现新的奥米克隆变种。与接种疫苗后痊愈的患者和接种第二剂奥米克隆变种疫苗后出现的突破性病例相反,我们最近对天真 Covishield 疫苗的研究显示免疫反应正在下降。这项研究和其他有关科维仙的研究结果表明,接种第二剂疫苗后,患者对奥米克隆的免疫反应较弱。因此有必要接种一剂预防疫苗以提高免疫力。COVID-19病例中感染BA.5、BA.4、BF.7、BQ.1、XBB和JN.1的病例激增,这些病例的传播性更强,疫苗效力明显下降。因此,在注射加强剂的同时,有必要用这些 SARS-CoV-2 变异株对现有疫苗进行调整。这些经改良的加强剂可增强对 SARS-CoV-2 感染的保护。
{"title":"The impact of Omicron on the COVID-19 vaccines: A review","authors":"Pragya D. Yadav ,&nbsp;Deepak Y. Patil ,&nbsp;Rima R. Sahay ,&nbsp;Anita M. Shete ,&nbsp;Sreelekshmy Mohandas ,&nbsp;Velu Nair","doi":"10.1016/j.vacune.2024.05.004","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.004","url":null,"abstract":"<div><p>The moment SARS-CoV-2 seemed to be receding; there was an uncertain emergence of Omicron variant which rapidly spread to all the 6 continents of the globe. The large number of genomic mutations has helped Omicron to evolve and become highly transmissible and escape the natural or vaccine-induced immune response. Until now, the Omicron has evolved into 5 unique lineages namely BA.1, BA.2, BA.3, BA.4, BA.5, and over 1000 sub-lineages. Despite vigorous COVID-19 immunisation programmes, India has been constantly being affected with emergence of new Omicron variants. In contrast to recovered patients following vaccination and breakthrough cases following a second dose against the Omicron variety, our recent research of naive Covishield vaccines showed declining immune response. The finding of this study and other studies with Covaxin depicted less immune response against Omicron post second dose of vaccination. This necessitates the administration of a preventive dose to improve immunity. There was surge in the COVID-19 cases with BA.5, BA.4, BF.7, BQ.1, XBB, and JN.1 infection which has greater transmissibility and vaccine efficacy remarkably dropped. Hence along with administration of booster dose, there is need to tweak the currently available vaccines with these SARS-CoV-2 variants. These types of modified boosters could provide enhances protection against SARS-CoV-2 infection.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 274-284"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State of the art in herpes zoster and new perspectives in its prevention 带状疱疹研究现状及预防新视角
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.001
José María Molero , Jesús Ortega , Irene Montoro , Natalia McCormick

Herpes zoster (HZ) is a relatively common disease whose incidence increases with age and in immunocompromised situations. Mortality caused by HZ is low, but its complications impact on physical, psychological, functional, and social aspects of patients, significantly reducing health-related quality of life. Post-herpetic neuralgia is the most common complication, and is characterised by symptoms of neuropathic pain including allodynia and hyperalgesia with electrical, burning, and/or stabbing sensations that persist more than 90 days. Its management is complex and has limitations, which increases the demand for health resources and also increases direct and indirect costs. This article reviews the epidemiological and clinical features of HZ, the available treatments and vaccines against HZ, as well as national and international vaccination recommendations. In addition, the role of primary care is emphasised as a catalyst for the implementation of adult vaccination.

带状疱疹(HZ)是一种比较常见的疾病,其发病率随着年龄的增长和免疫力下降而增加。HZ 造成的死亡率很低,但其并发症会影响患者的身体、心理、功能和社交方面,大大降低与健康相关的生活质量。带状疱疹后遗神经痛是最常见的并发症,主要表现为神经病理性疼痛,包括异感症和痛觉减退,并伴有电击、烧灼和/或刺痛感,持续时间超过90天。其治疗复杂且有局限性,增加了对医疗资源的需求,也增加了直接和间接成本。本文回顾了 HZ 的流行病学和临床特征、现有的 HZ 治疗方法和疫苗,以及国家和国际疫苗接种建议。此外,文章还强调了初级保健作为实施成人疫苗接种的催化剂的作用。
{"title":"State of the art in herpes zoster and new perspectives in its prevention","authors":"José María Molero ,&nbsp;Jesús Ortega ,&nbsp;Irene Montoro ,&nbsp;Natalia McCormick","doi":"10.1016/j.vacune.2024.05.001","DOIUrl":"10.1016/j.vacune.2024.05.001","url":null,"abstract":"<div><p>Herpes zoster (HZ) is a relatively common disease whose incidence increases with age and in immunocompromised situations. Mortality caused by HZ is low, but its complications impact on physical, psychological, functional, and social aspects of patients, significantly reducing health-related quality of life. Post-herpetic neuralgia is the most common complication, and is characterised by symptoms of neuropathic pain including allodynia and hyperalgesia with electrical, burning, and/or stabbing sensations that persist more than 90 days. Its management is complex and has limitations, which increases the demand for health resources and also increases direct and indirect costs. This article reviews the epidemiological and clinical features of HZ, the available treatments and vaccines against HZ, as well as national and international vaccination recommendations. In addition, the role of primary care is emphasised as a catalyst for the implementation of adult vaccination.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 254-263"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2445146024000281/pdfft?md5=fe1823f233f718625f156ab499d54133&pid=1-s2.0-S2445146024000281-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141040424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perceptions, attitude, and knowledge of Saudi parents towards the human papilloma virus vaccine 沙特父母对人类乳头瘤病毒疫苗的看法、态度和知识
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.008
Muazzam Sheriff Maqbul , Fatemah Saad Allihaydan , Rania Hisham Elfaham , Lina Abdulaziz Ahmed Baragaa , Shireen Hisham Elfaham , Nahlaa Saad Allihaydan , Abdulrahman Khalid Alswat , Salam Omar Alhilal , Reem Saleh Alzaki , Walaa Ebrahim Jaafar Jasim , Yousef Ahmed Alduhailan , Abdullah Dhafer Alshehri , Saeed Ayidh Alshahrani , Abdulrahman Musaed Al Sumaih

Objectives

HPV infection is a widely acknowledged cause of infection-related cancers globally. However, HPV vaccine is a reliable and risk-free method to avert HPV infection and is advised for children aged from 9 to 14, irrespective of their gender. Therefore, when considering the vaccination for human papilloma virus (HPV), viewpoints held by parents hugely impact their decision to vaccinate their daughters. This study aims to evaluate Saudi parents' comprehension and perception of HPV (human papilloma virus) and the HPV vaccine and its acceptability.

Methods

A cross-sectional study was conducted to investigate parents of adolescent daughters. An online questionnaire was conducted using Google form to gather information about socio-demographic data, awareness, and knowledge of HPV, and the willingness to accept the HPV vaccine.

Results

Out of 424 participants, three-quarters of the participants were mothers 319 (75.2%) and 105 (24.8%) were fathers. Over half of the respondents (53.8%) were acknowledged that HPV is a cause of cervical cancer where the relationship was found to be significant in relation to gender. Almost half of the participants (47.0%) were acknowledged that HPV vaccine is used to prevent cervical cancer which was statistically significant in relation to gender (P = .034) but (47.9%) did not know. Encouragingly, levels of vaccine acceptance were high (54.7%) although (41.0%) had a negative attitude towards the effectiveness of HPV vaccine with strong belief that the vaccine can cause serious side effects (67.0%). Parents with family history of cervical cancer and were aware that the vaccine can prevent cervical cancer were positively associated.

目标 人类乳头瘤病毒感染是全球公认的与感染有关的癌症病因。然而,人乳头瘤病毒疫苗是避免人乳头瘤病毒感染的可靠且无风险的方法,建议 9 至 14 岁的儿童接种,不论其性别如何。因此,在考虑接种人乳头状瘤病毒(HPV)疫苗时,父母所持的观点会对他们是否为女儿接种疫苗产生巨大影响。本研究旨在评估沙特父母对人类乳头瘤病毒(HPV)和 HPV 疫苗的理解和看法及其可接受性。使用谷歌表格进行了在线问卷调查,以收集有关社会人口学数据、对人乳头瘤病毒的认识和知识以及接受人乳头瘤病毒疫苗的意愿等信息。结果在 424 名参与者中,四分之三的参与者是母亲,占 319 人(75.2%),105 人(24.8%)是父亲。超过一半的受访者(53.8%)承认人乳头瘤病毒是宫颈癌的病因之一,并认为这与性别有显著关系。近一半的受访者(47.0%)知道 HPV 疫苗用于预防宫颈癌,这与性别有显著的统计学关系(P = .034),但也有 47.9% 的受访者不知道。令人欣慰的是,尽管(41.0%)的受访者对 HPV 疫苗的有效性持否定态度,并坚信疫苗会产生严重的副作用(67.0%),但他们对疫苗的接受程度很高(54.7%)。有宫颈癌家族史的家长和知道疫苗可以预防宫颈癌的家长呈正相关。
{"title":"Perceptions, attitude, and knowledge of Saudi parents towards the human papilloma virus vaccine","authors":"Muazzam Sheriff Maqbul ,&nbsp;Fatemah Saad Allihaydan ,&nbsp;Rania Hisham Elfaham ,&nbsp;Lina Abdulaziz Ahmed Baragaa ,&nbsp;Shireen Hisham Elfaham ,&nbsp;Nahlaa Saad Allihaydan ,&nbsp;Abdulrahman Khalid Alswat ,&nbsp;Salam Omar Alhilal ,&nbsp;Reem Saleh Alzaki ,&nbsp;Walaa Ebrahim Jaafar Jasim ,&nbsp;Yousef Ahmed Alduhailan ,&nbsp;Abdullah Dhafer Alshehri ,&nbsp;Saeed Ayidh Alshahrani ,&nbsp;Abdulrahman Musaed Al Sumaih","doi":"10.1016/j.vacune.2024.05.008","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.008","url":null,"abstract":"<div><h3>Objectives</h3><p>HPV infection is a widely acknowledged cause of infection-related cancers globally. However, HPV vaccine is a reliable and risk-free method to avert HPV infection and is advised for children aged from 9 to 14, irrespective of their gender. Therefore, when considering the vaccination for human papilloma virus (HPV), viewpoints held by parents hugely impact their decision to vaccinate their daughters. This study aims to evaluate Saudi parents' comprehension and perception of HPV (human papilloma virus) and the HPV vaccine and its acceptability.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted to investigate parents of adolescent daughters. An online questionnaire was conducted using Google form to gather information about socio-demographic data, awareness, and knowledge of HPV, and the willingness to accept the HPV vaccine.</p></div><div><h3>Results</h3><p>Out of 424 participants, three-quarters of the participants were mothers 319 (75.2%) and 105 (24.8%) were fathers. Over half of the respondents (53.8%) were acknowledged that HPV is a cause of cervical cancer where the relationship was found to be significant in relation to gender. Almost half of the participants (47.0%) were acknowledged that HPV vaccine is used to prevent cervical cancer which was statistically significant in relation to gender (<em>P</em> <!-->=<!--> <!-->.034) but (47.9%) did not know. Encouragingly, levels of vaccine acceptance were high (54.7%) although (41.0%) had a negative attitude towards the effectiveness of HPV vaccine with strong belief that the vaccine can cause serious side effects (67.0%). Parents with family history of cervical cancer and were aware that the vaccine can prevent cervical cancer were positively associated.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 181-192"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141324351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation analysis of gene expression between children with type 1 diabetes and Coxsackie viruses B 1 型糖尿病患儿与柯萨奇病毒 B 基因表达的相关性分析
Pub Date : 2024-04-01 DOI: 10.1016/j.vacune.2024.05.009
Zeyad Thonnoon Al-Rrassam

Type 1 diabetes is classified as an autoimmune disorder. Researchers observed the presence of viral Coxsackie virus B proteins within the β-cells in islets shortly after inoculating mice. This observation led them to establish a link between children who have T1D and an infection with the CVB. The objective of this research was to measure the degree of gene expression of highly expressed genes in individuals who were both infected with Coxsackie viruses B and previously had T1D. Additionally, levels of CVB IgG and HbA1c were assessed in the blood serum of patients with T1D.This correlation was assessed by analyzing the expression of genes with significantly extreme expression levels using logarithmic analysis with specialized mathematical software. This study revealed that there is an association between CVB IgG and HbA1c levels in T1D patients. Additionally, T1D patients with a family history of diabetes showed associations with genetic factors and gene expression. Interestingly, no significant differences in HbA1c levels were observed between patients based on their gender. Furthermore, the genes IGFBP5, GPNMB, and GJA1 exhibited a strong association with CVB. We propose a new strategy that may open up new therapy options for T1D caused by CVB through monitoring the physiological pathways of these genes.

1 型糖尿病被归类为自身免疫性疾病。研究人员观察到,小鼠接种后不久,胰岛β细胞内就出现了病毒性柯萨奇病毒B蛋白。这一观察结果使他们确定了患 T1D 的儿童与感染柯萨奇病毒 B 之间的联系。这项研究的目的是测量既感染过柯萨奇病毒 B 又曾患过 T1D 的人体内高表达基因的基因表达程度。此外,还对 T1D 患者血清中的 CVB IgG 和 HbA1c 水平进行了评估。通过使用专门的数学软件进行对数分析,对表达水平明显极端的基因的表达情况进行了分析,从而评估了这种相关性。这项研究表明,T1D 患者的 CVB IgG 与 HbA1c 水平之间存在关联。此外,有糖尿病家族史的 T1D 患者与遗传因素和基因表达也有关联。有趣的是,不同性别患者的 HbA1c 水平没有明显差异。此外,基因 IGFBP5、GPNMB 和 GJA1 与 CVB 有很强的相关性。我们提出了一种新策略,即通过监测这些基因的生理通路,为 CVB 导致的 T1D 开启新的治疗方案。
{"title":"Correlation analysis of gene expression between children with type 1 diabetes and Coxsackie viruses B","authors":"Zeyad Thonnoon Al-Rrassam","doi":"10.1016/j.vacune.2024.05.009","DOIUrl":"https://doi.org/10.1016/j.vacune.2024.05.009","url":null,"abstract":"<div><p>Type 1 diabetes is classified as an autoimmune disorder. Researchers observed the presence of viral Coxsackie virus B proteins within the β-cells in islets shortly after inoculating mice. This observation led them to establish a link between children who have T1D and an infection with the CVB. The objective of this research was to measure the degree of gene expression of highly expressed genes in individuals who were both infected with Coxsackie viruses B and previously had T1D. Additionally, levels of CVB IgG and HbA1c were assessed in the blood serum of patients with T1D.This correlation was assessed by analyzing the expression of genes with significantly extreme expression levels using logarithmic analysis with specialized mathematical software. This study revealed that there is an association between CVB IgG and HbA1c levels in T1D patients. Additionally, T1D patients with a family history of diabetes showed associations with genetic factors and gene expression. Interestingly, no significant differences in HbA1c levels were observed between patients based on their gender. Furthermore, the genes IGFBP5, GPNMB, and GJA1 exhibited a strong association with CVB. We propose a new strategy that may open up new therapy options for T1D caused by CVB through monitoring the physiological pathways of these genes.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 2","pages":"Pages 193-202"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141324352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Vacunas (English Edition)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1